Neobe Therapeutics Ltd
R&D
- Membership category
- Emerging Y3
Salisbury House, Station Road, Cambridge, CB1 2LA, United Kingdom
Neobe Therapeutics Ltd at a glance
About Neobe Therapeutics Ltd
Over 70% of patients with solid tumours do not respond to immunotherapies, in large part due the local tumour microenvironment, which can create fibrotic barriers to effective drug and immune cell infiltration. Neobe is developing a synthetic biology platform for the engineering of microscopic trojan horses that can break down these fibrotic components from within the tumour. Our programmable live biotherapeutics are designed to locally breakdown the stromal barriers to infiltration, enabling immunotherapy success in non-responding patients in a safe and targeted way. Neobe has two lead programs currently in preclinical development, with a focus on triple negative breast cancer and pancreatic adenocarcinoma and demonstrated safety and efficacy in vivo.